Search Within

William Thomas Johnson

  1. "Master of Science in Clinical and Translational Cancer Research "
Formats
  1. Meeting Abstract (4)
  2. Journal Article (1)
  3. Research Letter (1)
Groups
  1. CTCR Scholars (6)
  2. Center for Hematologic Malignancies (6)
  3. Department of Medicine (6)
  4. Hematologic Malignancies, Division of (6)
  5. Lymphoma (6)
  6. MSK Grad Students (6)

More Groups

People
  1. Anita Kumar (6)
  2. Ariela Noy (6)
  3. Gilles Salles (6)
  4. Lorenzo Falchi (6)
  5. Maria Palomba (6)
  6. Alison Moskowitz (5)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2021 (3)
Publications
  1. Blood (4)
  2. Haematologica (1)
  3. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (4)
  2. American Society of Clinical Oncology (1)
  3. Ferrata Storti Foundation (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
    Research Letter

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Pak, T.; Chang, T.; Dao, P.; Moskowitz, A. J.; Stuver, R. N.; Ghione, P.; Galasso, N.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save